CYP450 Enzymes

The cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing oxidative enzymes found mainly in the liver, but also in the gut, kidneys, lungs, and brain. They are responsible for metabolizing approximately 70-80% of all clinically used medicines, as well as endogenous substances such as steroid hormones, bile acids, and fatty acids. The name comes from the characteristic absorption peak at 450 nanometers when reduced and bound to carbon monoxide.

Humans have more than 50 CYP450 isoenzymes, but only a handful - CYP3A4, CYP2D6, CYP2C9, CYP2C19, CYP1A2, CYP2B6, and CYP2E1 - handle the bulk of medicine metabolism. CYP3A4 alone metabolizes nearly half of all marketed medicines. CYP2D6 has dramatic genetic variability: some patients are 'poor metabolizers' and others are 'ultra-rapid metabolizers,' which affects medicines from codeine and tramadol to tamoxifen and many antidepressants. CYP2C9 metabolizes warfarin and many NSAIDs; CYP2C19 metabolizes clopidogrel and several proton pump inhibitors.

Drug interactions involving CYP450 enzymes are among the most clinically important interactions in medicine. Inhibitors block enzyme activity, raising blood levels of substrate medicines and potentially causing toxicity. Strong CYP3A4 inhibitors include ketoconazole, itraconazole, clarithromycin, ritonavir, and grapefruit juice. Inducers do the opposite - they increase enzyme synthesis, lowering blood levels of substrates and potentially leading to treatment failure. Strong CYP3A4 inducers include rifampin, phenytoin, carbamazepine, and St. John's wort.

Clinically, CYP450 interactions explain why simvastatin combined with clarithromycin can produce rhabdomyolysis, why grapefruit juice interacts with so many medicines (amlodipine, simvastatin, certain immunosuppressants), why phenytoin reduces oral contraceptive efficacy, and why clopidogrel is less effective in CYP2C19 poor metabolizers. Pharmacogenomic testing for CYP2D6 and CYP2C19 variants is increasingly used to guide initial medicine selection - particularly for codeine, tamoxifen, clopidogrel, certain SSRIs, and warfarin.

A common misconception is that all medicine interactions involve CYP450 enzymes. Many do not - medicine transporters (P-glycoprotein, OATP), conjugation enzymes (UGTs, SULTs), and direct chemical chelation are also major mechanisms. Another misconception is that medicine labels list every important interaction. They list well-documented ones, but novel combinations may produce unexpected effects. A third misconception is that herbal products are too gentle to interact with CYP enzymes. St. John's wort is a potent CYP3A4 inducer that can reduce medicine levels enough to cause organ rejection, contraceptive failure, or HIV treatment failure.

Clinicians should screen new prescriptions against active medications using interaction-checking tools, ask specifically about herbal and OTC products, and consider pharmacogenomic testing when prescribing narrow-window medicines metabolized by polymorphic enzymes.